24 news items
Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
CADL
18 Jun 24
multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has
Candel Therapeutics' (NASDAQ: CADL) enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
CADL
14 Jun 24
microenvironment and the diversity of the tumor response to existing treatments. Using large patient datasets
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
, and atezolizumab yielded tumor response rates nearly triple historical results. Should the combination of pelareorep and mFOLFIRINOX produce a similarly
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
yielded tumor response rates nearly triple historical results. Should the combination of pelareorep and mFOLFIRINOX produce a similarly positive
Candel Therapeutics' (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers
CADL
7 Jun 24
to FDA-approved immune checkpoint inhibitor (ICI) treatments. Poor ICI treatment response has been
kwo5 faicbzmznebeajz
CADL
3 Jun 24
CAN-2409 administration. This reinforces the potential of CAN-2409 to activate a robust antitumoral immune response in patients with cancer also
yxu5gcg737l7xt7d
CADL
KRYS
MRNS
24 May 24
), together with standard of care (SoC) in patients with stage III/IV non-small cell lung cancer (NSCLC) who are non-responsive to immune checkpoint
v1zn04bcgw
AKAN
AKTS
BIOR
24 May 24
for Advanced Non-Small Cell Lung Cancer (NSCLC) in patients non-responsive to Immune Checkpoint Inhibitor (ICI) treatment at 2024 ASCO Annual Meeting
4d3gd6p6u0mwpltrb54uie1rxt0b9fuw17eygms31oiideszjrqhne6e5zue
CADL
23 May 24
CAN-2409 treatment resulted in activation of the systemic immune response after two administrations of CAN-2409, including increased numbers
1zh8gzzpm2d75eu02jihzejl4yoiho glpug
AZN
CADL
LTRN
23 May 24
. There is optimism within the Oncolytics team that improved response rates from the mFOLFIRINOX combination, compared
uwe2hzhm7ntag28agfotljk4anjylh efa4n813mpoaqu9c6p
AZN
CADL
LTRN
23 May 24
within the Oncolytics team that improved response rates from the mFOLFIRINOX combination, compared
c9kvrbgnh5rjm3ek ldz020qiyc94dgohxtchdil2hb
CADL
20 May 24
-tumor immune response. HSV-tk is an enzyme that locally converts orally administered valacyclovir into a toxic metabolite that kills nearby cancer cells
yulj2pk1h
ABVC
AMGN
CADL
15 May 24
combination demonstrates improvements in response rate over historical control trials, this treatment approach could move forward to a registration-enabling
t0sdimw5xbmrfquu3edov8a0j l1ej
ABVC
AMGN
CADL
15 May 24
demonstrates improvements in response rate over historical control trials, this treatment approach could move forward to a registration-enabling study
iw6z kp9yddaw8mtb8jx3bodd31cgj95g6ankj4zck1
AZN
CADL
HALO
9 May 24
."
Notably, Oncolytics plans to evaluate the correlation between tumor responses and the expansion of tumor
wu52xa 8ka7492j6bqyixsd6kalzt3c2445dl27vyeqw4
AZN
CADL
HALO
9 May 24
."
Notably, Oncolytics plans to evaluate the correlation between tumor responses and the expansion
pn6nkbwr71kxxod3fq4ma58ea
AZN
CADL
HALO
9 May 24
, Oncolytics plans to evaluate the correlation between tumor responses and the expansion of tumor-infiltrating lymphocytes (TILs
hwo510o2j4xdts5c3xfoq8 i10rzvv65c4vsncselhrkf31
AZN
CADL
HALO
9 May 24
, Oncolytics plans to evaluate the correlation between tumor responses and the expansion of tumor-infiltrating lymphocytes (TILs
ted4wr3remng97wurq8k1d dw3p3vcibtun76da7b4ajyoof
CADL
11 Apr 24
the activation of a robust systemic anti-tumor immune response.About Orphan Drug DesignationOrphan Drug Designation is granted
mmxq7xtd3ica24am2l5akf0fktksfzgd8bv598r7961v
CADL
9 Apr 24
Analytics suite, was shown to induce tertiary lymphoid structure formation, inhibit tumor growth, and improve response to immune checkpoint inhibitor